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Available online 29 December 2013Abstract In order to evaluate the functional significance of palmitoylation during multi-potent neural stem/progenitor cell
proliferation and differentiation, retinoic acid-induced P19 cells were used in this study as a model system. Cell behaviour was
monitored in the presence of the protein palmitoylation inhibitor 2-bromopalmitate (2BP). Here, we observed a significant reduction
in neuronal differentiation in the 2BP-treated cell model. We further explored the underlying mechanisms and found that 2BP
resulted in the decreased acetylation of histones H3 and H4 and interfered with cell cycle withdrawal and neural stem/progenitor
cells' renewal. Our results established a direct link between palmitoylation and the regulation of neural cell fate specification and
revealed the epigenetic regulatory mechanisms that are involved in the effects of palmitoylation during neural development.
© 2014 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
In the mammalian central nervous system, neural stem cells
can give rise to neural and glial progenitors that in turn
differentiate into neurons, astrocytes and oligodendrocytes
during neuronal differentiation (Hsieh et al., 2004; Malik et al.,☆ This is an open-access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and repro-
duction in any medium, provided the original author and source are
credited.
⁎ Corresponding author: Fax: +86 531 88382050.
E-mail address: aijunhao@sdu.edu.cn (A. Hao).
1873-5061/$ - see front matter © 2014 The Authors. Published by Elsevi
http://dx.doi.org/10.1016/j.scr.2013.12.0102013). This precise temporal and spatial differentiation of
neural subtypes is a tightly regulated process that is coordi-
nated by cell cycle regulation and cell fate determination
(Attia et al., 2007; Pao et al., 2011). In response to
differentiation signals, progenitor cells arrest cell divisions
and acquire differentiated features, but the molecular
mechanisms that control this event are not well defined.
It is becoming increasingly apparent that post-translational
lipidmodifications play a key role in cell fate specification and
cell survival and function by dynamically influencing protein
localization and function (Kurayoshi et al., 2007; Li et al.,
2011; Nakamura et al., 2013). Palmitoylation, which is a
post-translational modification, is catalysed by a family of 23
mammalian DHHC-domain-containing palmitoyl transferaseser B.V. All rights reserved.
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the past decade, 2-bromopalmitate (2BP), which is a non-
metabolisable palmitate analogue, has become deeply rooted
in the palmitoylation field, and it is often referenced as the
only pharmacological tool to block protein palmitoylation
(Coleman et al., 1992; Zheng et al., 2013). While many studies
have used 2BP-induced phenotypes as evidence of the
importance of palmitoylation in parasitic infection, osteoblast
differentiation and other cellular events, it is still poorly
understood how protein palmitoylation regulates neuronal
differentiation processes (Alonso et al., 2012; Leong et al.,
2009; Szkudelski and Szkudelska, 2011). In particular, the
targets of palmitoylation during neuronal development are
largely unknown.
Retinoic acid (RA)-induced P19 cells were used in this study
as amodel system to elucidate themolecular mechanisms that
control fate determination during neuronal differentiation.
Here, we observed that the inhibition of palmitoylation by 2BP
impaired neuronal differentiation and cell cycle exit. The
findings of this study also suggested that palmitoylation
modified P300 and that this modification might regulate
cellular events during neuronal differentiation, making it the
first study to demonstrate a key role of palmitoylation in
neuronal differentiation through an epigenetic mechanism.
2. Materials and methods
2.1. Cell culture
P19, which is a sub-clone of the mouse embryonic carcinoma
P19 cell line, was used in this study, and the methods were
performed as previously described (Jones-Villeneuve et al.,
1983; Wang et al., 2006). P19 cells were maintained in
Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher
Scientific, Inc.,Waltham,MA, USA) thatwas supplementedwith
10% foetal bovine serum (Life Technologies Corporation, Grand
Island, NY, USA) and 100 units/mL of penicillin–streptomycin
(Beyotime Institute of Biotechnology, Shanghai, China). For the
induction of neuronal differentiation, 1 × 105 cells/mL of P19
cells in DMEM were treated with 0.3 μM of all-trans-RA
(Sigma-Aldrich Co. LLC, St. Louis, MO, USA) and plated on
bacterial-grade dishes. After 4 days of culture in suspension in
the presence of RA, P19 cells formed embryonic body stages
(EBs). The EBs were collected from the suspension cultures and
dissociated into single cells by trypsin–ethylene-diamine-
tetra-acetic acid (Life Technologies Corporation). They were
then plated with a tissue culture surface in N2 medium (Life
Technologies Corporation). A palmitate analogue inhibitor, 2BP
(Sigma-Aldrich Co. LLC), was added to the cells at the
appropriate concentrations after 48 h of RA treatment. When
appropriate, 100 ng/mL of trichostatin A (TSA, Sigma-Aldrich
Co. LLC) was added to the medium for 24 h.
2.2. Quantitative real-time polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from P19 cells at different time points
with Trizol reagent (Life Technologies Corporation). Reverse
transcription was performed with 4 μg of total RNA with a
RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher
Scientific Inc.) and a random or oligo-dT primer. Transcriptlevels were determined by quantitative real-time polymerase
chain reaction (qRT-PCR) with iQSybr Green Supermix (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) and performed with
qTOWER 2.0, an RT-PCR Thermal Cycler (Analytik Jena AG,
Jena, Germany). Each amplification determination was done in
triplicate. The expression levels were calculated with the
delta-delta CT method, with β-actin serving as the normaliza-
tion control. The optimal primers for PCR were as follows: Oct4
(forward, 5′-ccaatcagcttgggctagag-3′; reverse, 5′-ctgggaaaggtg
tccctgta-3′); Nestin (forward, 5′-ctcgagcaggaagtggtagg-3′; re-
verse, 5′-gcctcttttggttcctttcc-3′); Sox2 (forward, 5′-gaacgcctt
catggtatggt-3′; reverse, 5′-tctcggtctcggacaaaagt-3′); β III-
tubulin (forward, 5′-tgaggcctcctctcacaagt-3′; reverse, 5′-cgc
acgacatctaggactga-3′); Neurog1 (forward, 5′-caccactctctgacc
ccagt-3′; reverse, 5′-gtcgtgtggagcaggtcttt-3′); Ki67 (forward,
5′-atccagatgatggagccaag-3′; reverse, 5′-atttctgcagctggtttgc
t-3′); P57 (forward, 5′-ggagcaggacgagaatcaag-3′; reverse,
5′-gttctcctgcgcagttctct-3′) and β-actin (forward, 5′-cctcta
tgccaacacagtgc-3′; reverse, 5′-cctgcttgctgatccacatc-3′).
2.3. Antibodies
The following primary antibodies were used in the study: mouse
anti-microtubule associated protein 2 (MAP2) antibody (EMD
Millipore Corporation, Billerica, MA, USA), mouse anti-β III-
tubulin antibody (Beyotime Institute of Biotechnology), mouse
anti-β-actin antibody (Sigma-Aldrich Co. LLC), mouse anti-Bax
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
mouse anti-Bcl-2 (Santa Cruz Biotechnology, Inc.), mouse
anti-Nestin antibody (EMD Millipore Corporation), rabbit anti-
Sox2 antibody (Abcam plc, Cambridge, MA, USA), rabbit
anti-Caspase-3 antibody (Cell Signaling Technology, Inc.,
Danvers, MA, USA), rabbit anti-cleaved Caspase-3 antibody
(Cell Signaling Technology, Inc.), rabbit anti-Histone H3
antibody (Cell Signaling Technology, Inc.), rabbit anti-
Acetyl-Histone H3 antibody (Cell Signaling Technology, Inc.),
rabbit anti-Histone H4 antibody (Cell Signaling Technology,
Inc.), rabbit anti-Acetyl-Histone H4 antibody (Cell Signaling
Technology, Inc.), rabbit anti-Oct4 antibody (Abcam plc), and
rabbit anti-P300 antibody (Santa Cruz Biotechnology, Inc.).
2.4. Immunofluorescence
The cells were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS; 20 mM NaH2PO4, 0.9% NaCl, pH 7.4),
permeabilised with 0.3% Triton X-100, and incubated with
the labelled primary antibodies overnight at 4 °C, which was
followed by incubation with appropriate secondary antibodies
that were conjugated to Alexa 488 or Alexa 568.
2.5. Western blot analysis
The cells were washed with cold PBS, lysed in ice-cold
radio-immunoprecipitation assay buffer with phenyl-methyl-
sulfonyl fluoride, and then centrifuged at 4 °C for 10 min.
Supernatantswere collected andmeasured by the bicinchoninic
acid method (Beyotime Institute of Biotechnology). Equal
amounts of each sample were separated by 10% sodium
dodecyl sulphate-polyacrylamide gel electrophoresis and then
electrotransferred to a poly-vinyl-idene fluoride membrane.
The membranes were blocked with 5% milk in Tris-buffered
Figure 1 2-Bromopalmitate (2BP) inhibited neuronal differentiation. (A) Therewas a significant reduction in differentiated neurons in the
2BP-treated cell model compared to the negative controls. Microtubule associated protein-2 (MAP2; green) immunostaining of P19-derived
neurons from control and 2BP-treated P19 cells that were differentiated for 6 days is shown. The percentage of MAP2-positive cells was
determined in differentiated cells. The values represent the mean of at least three independent experiments ± the standard error of the
mean (SEM). *P b 0.05 versus the control group. Scale bar, 100 μm. (B) There was a decrease in MAP2 protein expression in the 2BP-treated
cell model compared to that of the controls. A western blot analysis of the protein expressions of MAP2 from different durations during
neuronal differentiation is shown. U, untreated with 2BP; Aggregation, cells cultured in suspension in the presence of retinoic acid (RA)
without or with 2BP; Replating, cells were plated with a tissue culture surface at the differentiation stage.
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with primary and secondary antibodies. After washing with
TBST, the membranes were developed with an ECL detection
system (EMD Millipore Corporation).
2.6. Acyl-biotinyl exchange (ABE) method
The ABE assay for the determination of the palmitoylation level
was performed as previously described (Huang et al., 2009).
Briefly, after incubating with N-ethylmaleimide (Thermo Fisher
Scientific Inc.) to block free sulfhydryl groups on proteins,
samples were immunoprecipitated with anti-P300 (1 μg)
antibody. Purified precipitates or samples were treated with
or without 1 M HAM (Thermo Fisher Scientific Inc.) and 0.5 μM
Biotin-BMCC (Thermo Fisher Scientific Inc.) in order to label the
palmitoylation sites. The presence of Biotin on P300 proteins
was then analysed by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis with horseradish peroxidase-conjugated
anti-Streptavidin (Beyotime Institute of Biotechnology).
2.7. Cell viability assay
Cell viability was assessed by adding 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sartorius Corpo-
ration, Bohemia, NY, USA) to the cell cultures at a finalconcentration of 0.5 mg/mL. After a 1-h incubation at 37 °C,
the medium was carefully removed, and dimethyl sulfoxide
(Sartorius Corporation) was added to each well to lyse the
formazan crystals. The absorbance value of each sample was
immediately determined with a multi-well spectrophotometer
(Bio-Rad Laboratories, Inc.) at 490 nm. Three independent
experiments were conducted.2.8. Terminal deoxynucleotidyl transferase dUTP
nick-end labelling (TUNEL) assay
A TUNEL assay was conducted with an In Situ Cell Death
Detection Kit (Roche Diagnostics Corporation, Indianapolis,
IN, USA).2.9. Bromodeoxyuridine (BrdU) labelling of
proliferating cells
P19 cells, which were differentiated for 4 days, were
trypsinised and plated on glass coverslips. 5-Bromo-2-
deoxyuridine (BrdU, 40 μM, Sigma-Aldrich Co. LLC) was added
to themedium and incubated for 4 h before fixation. Cells were
then immunostained with an anti-BrdU antibody (EMD Millipore
Corporation).
Figure 2 Differentiation deficiencies in 2BP-treated cells. (A–D) Quantitative real-time polymerase chain reaction (qRT-PCR) kinetics of Oct4, Sox2, Nestin, and β-III-tubulin
expressions during the neuronal differentiation of control and 2BP-treated cells is shown. The values represent the mean of at least three independent experiments ± SEM. *P b 0.05,
**P b 0.01 versus the control group. #P b 0.05, ##P b 0.01 versus the 2BP-treated group. (E) Western blot analysis of the protein expressions of Oct4, Sox2, Nestin, and β-III-tubulin
from different durations during neuronal differentiation. Aggregation, cells cultured in suspension in the presence of RA without or with 2BP; Replating, cells were plated with a tissue
culture surface at the differentiation stage.
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Figure 3 The effects of 2BP on cell survival during neuronal differentiation. (A) 2BP improved the capacity for neural stem/progenitor cell renewal. During neuronal differentiation,
cell viability was affected by 2BP. MTT assays were performed after plating for the indicated times. The values represent the mean of at least three independent experiments ± SEM.
*P b 0.05, **P b 0.01 versus the control group. (B) During neuronal differentiation, there was no difference in the apoptotic cells in 2BP-treated cells compared to the control. A
terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) assay (green) was performed 4 days after plating. The percentage of TUNEL-positive cells was determined. The
values represent the mean of at least three independent experiments ± SEM.
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486 X. Chen et al.2.10. Flow cytometry analysis of cell
cycle distribution
Cells were trypsinised, collected by centrifugation, resus-
pended and washed in PBS before being fixed in 75% ethanol
for 1 h at room temperature. Fixed cells were incubated
with propidium iodide (20 μg/mL) and RNase A (10 mg/mL)
for 30 min. The cell cycle was analysed with a FC500 flowcytometer (Beckman Coulter, Inc., Indianapolis, IN, USA),
and the data were analysed with WinMDI software.2.11. Image and statistical analysis
Images were acquired with a fluorescent microscope
(IX71; Olympus Corporation, Tokyo, Japan) for immunostaining.
4872-Bromopalmitate modulates neuronal differentiation through histone acetylation regulationImages were adjusted for brightness and contrast with Image-
Pro Plus 6.0.
Each experiment was repeated at least three times.
The data shown are expressed as the mean ± the standard
error of the mean (SEM). Student's t-tests were used to
compare the effects of all treatments. Differences were
considered statistically significant with P values less than
0.05 (* or #, P b 0.05; ** or ##, P b 0.01; and *** or ###,
P b 0.001).3. Results
3.1. 2BP inhibited neuronal differentiation
2BP inhibition is thought to block protein palmitoylation, with
a half maximal inhibitory concentration (IC50) of 10–15 μM
(Zheng et al., 2013). As shown in Figure S1, cells that were
treated with 10 μM of 2BP did not exhibit increased cell death
or obvious cytotoxicity compared to control cells at the
aggregation stage. Thus, we performed the remaining studies
with a concentration of 10 μM.
In order to elucidate the effects of palmitoylation on
neuronal differentiation, we examined the neuronal marker,
MAP2, after plating with immunofluorescent staining. As
shown in Fig. 1A, a significant reduction in the percentage of
MAP2-positive cells was observed in 2BP-treated cells com-
pared to the negative control. A decrease in MAP2 protein
expression was also detected with a western blot analysis
(Fig. 1B).
In order to define whether the early steps of the differen-
tiation process were equally affected in the 2BP-treated cell
model, the Oct4, Nestin, Sox2, and β III-tubulin gene markers
were examined with qRT-PCR. After RA induction, the express-
ion of Oct-4 was lost, and there were no obvious differences
between 2BP-treated and untreated cells (Fig. 2A). However,
cells that were treated with 2BP expressed higher levels of Sox2
and Nestin, notably during differentiation (Figs. 2B and C). This
apparent increase in neural stem/progenitor cells was in
agreement with the results of the western blot and immunoflu-
orescent staining analysis (Figs. 2E and S2). Once attached,
however, cells that were treated with 2BP expressed reduced
levels of β III-tubulin (Figs. 2D and E). These data suggested
that, while cells that were treatedwith 2BP produced increased
numbers of neural stem/progenitor cells, their differentiation
to neurons was less efficient.Figure 4 2BP modulated the cell cycle profile during neuronal d
more dividing cells in the 2BP-treated group than that of control. An
immunofluorescence analysis. The percentage of BrdU-positive cell
independent experiments ± SEM. *P b 0.05 versus the control group
cellular divisions than the control cells. The cells were labelled with
Far Red (FR) kinetics was analysed by fluorescence activated cell s
which was covalently bound to the cell membrane, diminished by ha
represented by dark lines and the white region, and the results for t
region. (C) The percentage of S-phase cells was increased significan
2BP-treated cells compared to control cells. Representative (n = 3
percentages of cells in each phase of the cell cycle were determine
experiments ± SEM. *P b 0.05 versus the control group.3.2. 2BP changed the cell cycle profile during
neuronal differentiation
We next turned our attention to estimating the survival of the
2BP-treated cell model during differentiation by employing a
MTT assay. As shown in Fig. 3A, the number of attached cells in
control cultures did not change between 12 h and 6 days of
plating, indicating that the attached cells did not undergo
obvious proliferation. In contrast, after 6 days of plating, the
number of cells was significantly increased compared to that
after 12 h of plating in 2BP-treated cells. Besides, the TUNEL
results showed that 2BP resulted in 4% of apoptotic cells
compared to 8% apoptosis in normally differentiating cells, but
the difference was not significant (Fig. 3B). These results
indicated that, during neuronal differentiation, 2BP improved
the capacity for neural stem/progenitor cell renewal and
hampered the passage of neural stem/progenitor cells to form
differentiated neurons.
In order to test whether cells that were treated with 2BP
had an enhanced capacity for cell division, we used a series of
BrdU incorporation assays to assess cell proliferation during
differentiation. The results showed that the percentage of
BrdU-positive cells was 21% in 2BP-treated cells compared to
controls that showed only 3% BrdU-positive cells after
4 days of plating (P = 0.0238) (Fig. 4A). The enhanced
capacity for cell division was also detected by membrane-
labelling experiments at day 4 of differentiation in suspen-
sion culture. A fluorescence-activated cell sorting (FACS)
analysis revealed that cells that were treated with 2BP lost
fluorescence more rapidly during the initial 24 h of culture
after labelling than control cells did, indicating that they
had undergone more cellular divisions than control cells or
that they contained more dividing cells (Fig. 4B).
Next, we tested the hypothesis that the increase in the
neural stem/progenitor cell numbers of 2BP-treated cells was
associatedwith changes in cell cycle distributionwith FACS. As
expected, the percentage of S-phase cells was increased
significantly, while the percentage of G1/G0-phase cells was
reduced in 2BP-treated cells compared to control cells,
indicating their inability to arrest cell division and to induce
neuronal differentiation (Fig. 4C). We further examined the
expression of cell cycle regulators during neuronal differenti-
ation between control and 2BP-treated cells with qRT-PCR
(Figure S3). Among them, the levels of Ki67, which is a
proliferative marker, in 2BP-treated cells showed a two-fold
increase, while the expression of P57, which promotes cellifferentiation. (A) During neuronal differentiation, there were
anti-bromodeoxyuridine (BrdU) antibody (red) was used in the
s was determined. Values represent the mean of at least three
. Scale bar, 200 μm. (B) The 2BP-treated cells underwent more
CellTrace Far Red on day 4 of suspension culture, and the 24-h
orting (FACS). The fluorescence intensity of the CellTrace dye,
lf at each cellular division. The results for the control cells are
he 2BP-treated cells are represented by dark lines and the grey
tly, while the percentage of G1/G0-phase cells was reduced in
) flow cytometric data showing the cell cycle distribution. The
d. The values represent the mean of at least three independent
Figure 5 Involvement of histone acetylation in 2BP-mediated neuronal differentiation of P19 cells. (A, C) During neuronal
differentiation, there was a significant reduction in the percentage of acetylation H3- (A, red) and H4- (C, red) positive cells detected
compared to that of the control cells. Scale bar, 200 μm. (B) There was an abundance of acetylated H3 or H4 in differentiated cells
compared to undifferentiated cells, but less histone H3 or H4 acetylation in the 2BP-treated cell model compared to the control cells.
Western blot analysis of the protein expressions of acetylated histones H3 and H4. Un, untreated with 2BP. (D) TSA appeared to
increase neuronal differentiation as shown by the expression of β III-tubulin. Western blot analysis of the protein expression of
β-III-tubulin 24 h after trichostatin A (TSA) treatment.
Figure 6 2BP hampered the nuclear import of P300 and inhibited its palmitoylation status. (A) In 2BP-treated cells, an
immunofluorescent staining analysis of P300 exhibited peri-nuclear localization rather than nuclear localization, as in control cells.
Scale bar, 20 μm. (B) During neuronal differentiation, therewas reduced palmitoylation of P300 in 2BP-treated cells compared to control.
The acyl-biotinyl exchange (ABE) method was performed 4 days after neuronal differentiation.
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edly decreased (Figures S3A and S3B).
Taken together, these results suggested that the reduc-
tion in the differentiation capacity of 2BP-treated cells was
most likely due to increased neural stem/progenitor cell
renewal, in which the neural stem/progenitor cells were
delayed in cell cycle progression and unable to exit the cell
cycle on time.
3.3. 2BP impaired the acetylation status of histones
H3 and H4
As reported, the P57 gene, which is epigenetically regulated,
can be activated by TSA, which is a histone deacetylase
inhibitor (Attia et al., 2007; Sato et al., 2005). Indeed, while
the alteration of certain neuronal markers, such as Nestin,
Sox2, and β III-tubulin, was confirmed, some of the deregulated
genes were associated with a wide range of cellular functions
rather than being restricted to neuron-specific expression and
function (Figure S4). These results suggested that one
mechanism by which 2BP might regulate the expression of
target genes, such as P57, Nestin, and β III-tubulin, was
through the regulation of histone acetylation during neuronal
differentiation.
In order to detect changes in histone acetylation, protein
extracts were harvested from 2BP-treated and 2BP-untreated
cells and analysed by a western blot analysis with antibodies
that were specific for the acetylated histones H3 and H4. We
detected an abundance of acetylated H3 in differentiated
cells compared to undifferentiated cells (Fig. 5B). However,
there appeared to be less histone H3 acetylation in the
2BP-treated cell model compared to control cells (Fig. 5B).
The immunofluorescent staining analysis supported this
finding, and, in 2BP-treated cells, a significant reduction in
the percentage of acetylation H3–positive cells was detected
compared to control cells (Fig. 5A). We also observed a similar
change in the expression levels of acetylated histone H4
following 2BP treatment (Figs. 5B and C).
Next, in order to test whether increased histone acetyl-
transferase (HAT) activity could rescue the 2BP-induced
phenotype during neuronal differentiation, we treated cells
with TSA for 24 h. qRT-PCR results showed that, while P57
expression was strongly increased by TSA treatment in both
the untreated and treated cells (Figure S3B), the expression
levels of Sox2 and Nestin were abolished by TSA treatment
(Figs. 2B and C). TSA appeared to increase neuronal differen-
tiation as shown by the expression of β III-tubulin (Figs. 2D
and 5D). Interestingly, after TSA treatment, the β III-tubulin
levels of the cells that were treated with 2BP were even
higher than those of untreated cells (Figs. 2D and 5D). Our
data suggested that the delay in the differentiation process in
2BP-treated cells could be rescued by increased HAT activity,
and the inverted kinetics might be interpreted as a conse-
quence of the simultaneous differentiation of the 2BP-treated
cell model.
3.4. 2BP hampered the nuclear import of P300 and
inhibited its palmitoylation status
We attempted to understand the basis for the 2BP-
associated effects on HAT. Because 2BP itself has not beenreported to have intrinsic histone deacetyltransferase activ-
ity, one possibility was that it acted through the inhibition of
HATs, such as P300, which is a protein that has the capacity to
acetylate histones H3 and H4 both in vitro and in vivo
(Marmorstein and Trievel, 2009). Interestingly, we found a
change in the sub-cellular localization of P300 in the immuno-
fluorescent staining analysis (Fig. 6A). We detected relatively
high levels of P300 in the nucleus of control cells. However,
there appeared to be an abundance of P300 in the cytoplasm
of 2BP-treated cells, indicating that 2BP might impair the
nuclear import of P300 after translation.
The post-translational modifications of proteins with lipids
provide an important mechanism for regulating protein sub-
cellular localization, stability, trafficking, and other aspects
of protein function (Aicart-Ramos et al., 2011; Resh, 2012).
Because 2BP is widely used as an inhibitor of protein
palmitoylation, one possibility is that 2BP impairs the nuclear
import of P300 by inhibiting its palmitoylation status. As
predicted by the CSS-Palm 2.0 software, P300 has numerous
potential palmitoylation sites (Table S1), which are conserved
in P300 from different species. In order to detect changes in
the palmitoylation of P300, protein extracts were immuno-
precipitated with P300 and analysed by the acyl-biotinyl
exchange (ABE) method. A significant reduction in the
palmitoylation level of P300 was observed in 2BP-treated
cells compared to control cells (Fig. 6B).
Taken together, these results suggested that 2BP inhibited
P300 palmitoylation and hampered the nuclear import of
P300, resulting in a change in the histone H3 and H4 acetyla-
tion status in differentiation cells.4. Discussion
Neuronal differentiation is essential for the formation of the
mammalian nervous system. In this series of experiments, we
used awell-establishedmodel system of P19 cells to investigate
the connection between palmitoylation and neural cell fate
specification. When cells were cultured in the presence of a
palmitoylation inhibitor, 2BP, their differentiation to neurons
was less efficient. These effects were associated with an
extensive change in the transcriptional profile of neural stem/
precursor cells and a decrease in acetylated histones H3 andH4.
Our findings thus established a role of palmitoylation in the
epigenetic regulation of genetic expression during neuronal
differentiation and provided a novel insight into the function of
palmitoylation during vertebrate development.
Neuronal differentiation is a tightly regulated process that
is coordinated with cell cycle regulation and cell fate deter-
mination (Galderisi et al., 2003; Nguyen et al., 2006). The
regulation of gene expression during this event is governed by
a number of mechanisms at the transcriptional level, including
epigenetics (Felling et al., 2012; Mehler, 2008). Here, we
showed that 2BP delayed neuronal differentiation and
increased neural stem/precursor cell renewal and mainte-
nance. It appeared likely that these cellular phenotypes were
associated with altered transcriptional activity in cells that
were treated with 2BP. One of the genes that was down-
regulated in the cells that were treated with 2BP was the P57
gene, which is a member of the Cip/Kip family, which is
important in regulating cell proliferation and differentiation
during neurogenesis (Galderisi et al., 2003; Itoh et al., 2007).
490 X. Chen et al.The rather subtle transcriptional down-regulation of P57 may
indicate a role of 2BP in the epigenetic modulation of basal
transcription levels rather than in the specific activation of a
subset of neurally expressed genes. Such a role would
correlate with our finding that, except for Sox2, Nestin, and
β III-tubulin, 2BP also altered some non-neuron-specific gene
expressions, including that of Rnd2, Vamp3, and Igf2, in the
cell model.
The acetylation status of histones is thought to act as a
general regulator of chromatin structure, which mediates the
removal of epigenetically controlled repression and enhances
transcriptional activity (Sterner and Berger, 2000; Struhl,
1998). Recently, studies have provided evidence for general
alterations in histone modification, such as increased histone
H3 and H4 acetylation during neuronal differentiation (Hsieh
et al., 2004; Lee and Lee, 2010; Saraiva et al., 2010). As
expected, our findings showed that 2BP impaired the acetyla-
tion status of histones H3 and H4; moreover, the increased HAT
activity rescued the 2BP-induced phenotype during neuronal
differentiation. However, other studies have suggested that
postmitotic neurons can no longer rely on replication-
dependent machinery to renew or modify their chromatin-
bound histone pool (Attia et al., 2007). It is possible that
there are certain histone variants in such cells that can
be incorporated into nucleosomes in a DNA replication-
independent manner in order to maintain and establish
chromatin modification-dependent gene expression patterns
(Ahmad and Henikoff, 2002; Bosch and Suau, 1995; Chow et al.,
2005).
Protein function is affected by its expression level,
subcellular localization, interaction with other proteins and
its post-translational modifications (Aicart-Ramos et al., 2011;
Johnson et al., 1994; Linder and Deschenes, 2007; Zhang and
Casey, 1996). Our findings suggested that an inhibition of
neuronal differentiation and a reduction of acetylation in
histones H3 and H4 indeedwere a reflection of the dysfunction
of P300. Fortunately, these findings were similar to the
observation that mice that were nullizygous for p300 died
between days E9 and E11.5 of gestation and exhibited strong
defects in neurulation and cell proliferation (Yao et al., 1998).
Further analysis of the mechanism of 2BP-mediated P300
activity revealed that, during neuronal differentiation, 2BP
impaired the nuclear import of P300, and this was, at least in
part, associated with a lower P300 palmitoylation status. This
change in the P300 palmitoylation status was different from
that of osteoblasts or cardiomyocytes that were treated with
2BP, indicating that different cell types may have specific sets
of palmitoylated proteins (Hasselbaink et al., 2002; Leong et
al., 2009). Lipid-modified nuclear proteins are considered
bio-molecular oddities because their reduced mobility and
membrane attachment appear to contradict the nuclear
import that is required for their gene-regulatory function
(Zupicich et al., 2001). Recently, more and more nuclear
proteins have been found to be lipid-modified, including
NFAT5a, which is an osmo-sensitive transcription factor in
mammalian cells (Eisenhaber et al., 2011). The abilities for
myristoylation and palmitoylation are critical for NFAT5a
temporary accumulation at the plasmamembrane, but high salt
stress initiates the translocation of NFAT5a from the plasma
membrane into the nucleus despite lipid anchoring. Previous
investigations have indicated that protein palmitoylation
mainly occurs in the Golgi apparatus and endoplasmicreticulum, and we therefore suggest that palmitoylation is
required for P300 accumulation at a peri-nuclear compartment,
making it more conducive to nuclear import (Aicart-Ramos et
al., 2011; Huang et al., 2009; Linder and Deschenes, 2007).
In conclusion, we demonstrated that 2BP can impair
histone H3 and H4 acetylation and the neuronal differentia-
tion of P19 cells. Our results established a direct link between
palmitoylation and the regulation of neural cell fate specifi-
cation and development, indicating that its alterations can
lead to defects in the neural system. This study revealed for
the first time that epigenetic regulatory mechanisms were
involved in the effects of palmitoylation on neuronal differ-
entiation. Further investigations of the mechanisms by which
improper palmitoylation leads to neurological disorders and
disease processes are required.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.12.010.
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